Landon Inge – “LKB1 and Non-Small Cell Lung Cancer: Can understanding the functions of the LKB1 tumor suppressor lead us to new treatments?”

Speaker: Landon J. Inge, PhD. holds a B.S. in Cellular and Molecular Biology from the University of Arizona and a Ph.D. in Cellular Molecular Pathology from the University of California, Los Angeles. He is member of the Center for Thoracic Disease and Transplantation at St. Joseph’s Hospital and Medical Center, where he focused upon identifying new avenues for treating Non-small cell lung cancer and esophageal adenocarcinoma. He has a specific interest in characterizing how loss of the LKB1 tumor suppressor alters the cellular functions within lung cancer cells and utilizing this information to develop therapeutic treatments.

Location: Biodesign Auditorium

Web Cast: View Web Cast

Date & Time: November 15th, 2012 12:00 p.m.

Title: LKB1 and Non-Small Cell Lung Cancer: Can understanding the functions of the LKB1 tumor suppressor lead us to new treatments?

Abstract: Lung cancer, and more specifically non-small cell lung cancer (NSCLC), is the primary contributor to cancer related mortalities within the United States and accounts for the majority (~80{236bd5e292587b885399ce1fe93b84c86ca4f34851d3c4bf06f3f0da35a3ccbb}) of lung cancers compared to the other subtypes. Due to limited choices in treatment (surgical resection, chemotherapy and radiation), significant work has identified unique genetic alterations within NSCLC tumors in hopes of utilizing this information to develop improved treatment modalities. Genetic inactivation of the tumor suppressor gene, LKB1/STK11, is frequent in NSCLC and contributes to NSCLC disease progression. The unique regulatory functions of LKB1, combined with the increased frequency of inactivation in NSCLC, have resulted in considerable interest in developing therapies targeted towards LKB1 null NSCLC. In this talk, I will discuss the current understanding of LKB1’s regulatory functions and contribution of LKB1 loss to NSCLC progression, as well as our and others attempts to tailor treatments towards LKB1 null NSCLC.

Thank you and if you have questions please contact Amanda Wilber! And don’t forget, coffee will be served!

Amanda Wilber, Center for the Convergence of Physical Science and Cancer Biology

Arizona State University | P.O. Box 871504 | Tempe, AZ 85287

480.965.3860 | Fax: 480.965.6362
email hidden; JavaScript is required

Leave a Reply